Logos Capital

Logos Capital is a fundamental biotechnology-focused fund that seeks to combine in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare.

Based in San Francisco, Logos combines expertise across medical, scientific, and statistical disciplines to expand the depth of diligence in identifying compelling investment ideas and uncorrelated-market returns. They combine scientific diligence with their statistical modeling of clinical trials to achieve the highest levels of conviction in each position.

Logos Capital, established in 2019 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture, Seed investments across Financial Services, Venture Capital, Biotechnology, Finance, Business Development, Financial Exchanges, Enterprise Software, Customer Service, Service Industry, Funding Platform. The organization boasts a portfolio of 119 investments, with an average round size of $124.6M and 72 successful exits. Their recent investments include Omega Funds, T. Rowe Price, Abrdn, Foresite Capital, Hillhouse Investment. The highest investment round they participated in was $2108.0B. Among their most notable exits are Omega Funds and T. Rowe Price. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.